EMA & FDA Hold Workshop to Study Drug-related PML

Some 170 experts and stakeholders discussed a common way forward for research in drug-related PML, including possibilities for funding and partnerships, and mechanisms for information sharing.

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) recently held a two-day workshop in London on drug-related progressive multifocal leukoencepalopathy (PML). The meeting aimed to bring together experts and stakeholders of PML to identify research questions that will address knowledge gaps in order to reduce the burden of the disease.

Some 170 experts and stakeholders from regulatory authorities, research funding bodies, academic and clinical researchers, patients and healthcare representatives and industry discussed a common way forward for research in drug-related PML, including possibilities for funding and partnerships, and mechanisms for information sharing.

PML is a rare, debilitating and sometimes fatal d